Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal Medical Laboratory Technology Journal
Tuba Hacıbekiroğlu
Department of Hematology, Sakarya University Hospital, Medical Faculty, Sakarya, Turkey
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Nursing Public Health

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Early Relapse After Autologous Stem Cell Transplantation in Multiple Myeloma is Still Prognostic in The Era of Novel Agents Semih Başcı; Tuğçe Nur Yiğenoğlu; Bahar Uncu Ulu; Mehmet Bakırtaş; Derya Şahin; Tahir Darçın; Jale Yıldız; Alparslan Merdin; Nuran Ahu Baysal; Dicle İskender; Merih Kızıl Çakar; Mehmet Sinan Dal; Tuba Hacıbekiroğlu; Fevzi Altuntaş
Medical Laboratory Technology Journal Vol. 6 No. 2 (2020): December
Publisher : Poltekkes Kemenkes Banjarmasin Jurusan Analis Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (19.931 KB) | DOI: 10.31964/mltj.v6i2.281

Abstract

Significant improvements in the prognosis of Multiple Myeloma(MM) have recently observed in the era of novel agents. Induction treatment, including new agents followed by conditioning regimen and upfront autologous stem cell transplantation(ASCT), has been accepted as the standard treatment approach for newly diagnosed eligible MM patients. Despite novel agents, upfront ASCT is still superior to conventional chemotherapy alone. Previous studies revealed that the duration between ASCT and relapse had predicted overall survival(OS), and meantime, it was widely used to determine the potential benefit from a second ASCT. However, the majority of the data collected reflects the treatment modalities before novel agents. In this study, we aimed to investigate the impact of post-transplantation early relapse(ER) on survival in the era of novel agents. The results of 155 MM patients that underwent ASCT at our center between January 2010 and May 2018 were analyzed retrospectively. The median follow-up duration was 20 months in the ER group, 27 months in the non-ER group, and 24 months in all patients. 33.3% of patients in the ER group and 71.4% of patients in the non-ER group were alive at the time of analysis. Median OS was 20.77±3.66 months in the ER group and 40.89±4.21 months in the non-ER group. We found a statistically significant relationship between the ER and the poor OS (p:
Co-Authors Alparslan Merdin Bahar Uncu Ulu Derya Şahin Dicle İskender Fevzi Altuntaş Jale Yıldız Mehmet Bakırtaş Mehmet Sinan Dal Merih Kızıl Çakar Nuran Ahu Baysal Semih Başcı Tahir Darçın Tuğçe Nur Yiğenoğlu